- Home
- VTYX vs DMF Comparison
VTYX vs DMF Comparison
Compare VTYX & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- DMF
- Stock Information
- Founded
- VTYX 2018
- DMF 1988
- Country
- VTYX United States
- DMF United States
- Employees
- VTYX N/A
- DMF N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- DMF Finance/Investors Services
- Sector
- VTYX Health Care
- DMF Finance
- Exchange
- VTYX Nasdaq
- DMF Nasdaq
- Market Cap
- VTYX 154.9M
- DMF 152.2M
- IPO Year
- VTYX 2021
- DMF N/A
- Fundamental
- Price
- VTYX $1.07
- DMF $7.21
- Analyst Decision
- VTYX Buy
- DMF
- Analyst Count
- VTYX 4
- DMF 0
- Target Price
- VTYX $11.33
- DMF N/A
- AVG Volume (30 Days)
- VTYX 731.3K
- DMF 60.7K
- Earning Date
- VTYX 05-08-2025
- DMF 01-01-0001
- Dividend Yield
- VTYX N/A
- DMF 2.66%
- EPS Growth
- VTYX N/A
- DMF N/A
- EPS
- VTYX N/A
- DMF 0.15
- Revenue
- VTYX N/A
- DMF N/A
- Revenue This Year
- VTYX N/A
- DMF N/A
- Revenue Next Year
- VTYX N/A
- DMF N/A
- P/E Ratio
- VTYX N/A
- DMF $45.13
- Revenue Growth
- VTYX N/A
- DMF N/A
- 52 Week Low
- VTYX $1.07
- DMF $5.37
- 52 Week High
- VTYX $5.66
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- VTYX 23.19
- DMF 48.84
- Support Level
- VTYX $1.28
- DMF $7.13
- Resistance Level
- VTYX $1.37
- DMF $7.29
- Average True Range (ATR)
- VTYX 0.08
- DMF 0.07
- MACD
- VTYX -0.01
- DMF -0.01
- Stochastic Oscillator
- VTYX 0.00
- DMF 32.00
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.